The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor

Nature Medicine
S BasuD Mukhopadhyay

Abstract

Angiogenesis has an essential role in many important pathological and physiological settings. It has been shown that vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), a potent cytokine expressed by most malignant tumors, has critical roles in vasculogenesis and both physiological and pathological angiogenesis. We report here that at non-toxic levels, the neurotransmitter dopamine strongly and selectively inhibited the vascular permeabilizing and angiogenic activities of VPF/VEGF. Dopamine acted through D2 dopamine receptors to induce endocytosis of VEGF receptor 2, which is critical for promoting angiogenesis, thereby preventing VPF/VEGF binding, receptor phosphorylation and subsequent signaling steps. The action of dopamine was specific for VPF/VEGF and did not affect other mediators of microvascular permeability or endothelial-cell proliferation or migration. These results reveal a new link between the nervous system and angiogenesis and indicate that dopamine and other D2 receptors, already in clinical use for other purposes, might have value in anti-angiogenesis therapy.

References

Aug 1, 1978·The Journal of Investigative Dermatology·M M Wick
Mar 18, 1985·Journal of Immunological Methods·K HeegH Wagner
Jan 1, 1987·Journal of Cancer Research and Clinical Oncology·P S Dasgupta, T Lahiri
Feb 7, 1998·Current Opinion in Neurobiology·M F Egan, D R Weinberger
Apr 15, 1999·Annual Review of Neuroscience·C W Olanow, W G Tatton
May 11, 1999·Digestive Diseases and Sciences·S Basu, P S Dasgupta
Jan 15, 2000·Journal of Neuroimmunology·S Basu, P S Dasgupta
Feb 1, 2000·Laboratory Investigation; a Journal of Technical Methods and Pathology·A PetterssonH F Dvorak
Aug 30, 2000·Endocrine·S Basu, P S Dasgupta
Sep 13, 2000·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·Y NagaiK Kobayashi
Oct 12, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·L E MillerR H Straub
Oct 18, 2000·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·V L ChamaryG Burnstock

❮ Previous
Next ❯

Citations

Feb 21, 2013·Angiogenesis·Michael S RogersRobert J D'Amato
May 16, 2013·Cancer Metastasis Reviews·Ming ShiNing Guo
Aug 14, 2012·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Chandrani SarkarSujit Basu
Jan 28, 2009·Endocrine Pathology·María Susana Mallea-GilDamasia Becu-Villalobos
Jun 30, 2011·Journal of Medicinal Chemistry·Cristina FanteFrancesca Greco
Oct 5, 2011·Nano Letters·Chitta Ranjan PatraDebabrata Mukhopadhyay
Jul 17, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hanna S LindgrenM Angela Cenci
Feb 25, 2006·Nature Reviews. Cancer·Michael H AntoniAnil K Sood
Sep 3, 2003·Nature Reviews. Genetics·Peter Carmeliet
Oct 28, 2003·DNA and Cell Biology·O Guntinas-Lichius, C Wittekindt
Jun 22, 2012·Human Reproduction Update·M W Laschke, M D Menger
Apr 9, 2010·Current Opinion in Hematology·Harold F Dvorak
Oct 18, 2011·American Journal of Physiology. Lung Cellular and Molecular Physiology·Pawan K VohraDebabrata Mukhopadhyay
May 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Myrthala Moreno-SmithAnil K Sood
Mar 15, 2008·The Journal of Clinical Investigation·Debanjan ChakrobortySujit Basu
Apr 15, 2010·The Journal of Clinical Investigation·Anil K SoodSusan K Lutgendorf
Nov 1, 2006·Journal of Nanobiotechnology·Chitta Ranjan PatraDebabrata Mukhopadhyay
Oct 27, 2007·Reproductive Biology and Endocrinology : RB&E·Veronica Rey-AresArtur Mayerhofer
Jul 30, 2008·Journal of Molecular Signaling·Resham BhattacharyaDebabrata Mukhopadhyay
Dec 24, 2010·PLoS Neglected Tropical Diseases·Denise G Martinez-LopezJenifer Coburn
Sep 29, 2011·PloS One·Saurav ShomeSujit Basu
May 23, 2012·PloS One·Michael S RogersRobert J D'Amato
Dec 15, 2010·Future Oncology·Myrthala Moreno-SmithAnil K Sood
Aug 25, 2011·Reproduction : the Official Journal of the Society for the Study of Fertility·Francisco Delgado-RosasAntonio Pellicer
Aug 30, 2001·Proceedings of the National Academy of Sciences of the United States of America·J LahdenrantaW Arap
Apr 22, 2014·Archives of Gynecology and Obstetrics·Amr M Salaheldin Abdel HamidMary P Roberts
May 29, 2010·Journal of Oncology·Jason Tilan, Joanna Kitlinska
Jan 18, 2006·Pituitary·N Garcia de la TorreJ A H Wass
Oct 30, 2008·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Begoña Villar-ChedaJose L Labandeira-Garcia
Nov 10, 2009·Journal of Biomedical Optics·Junjie YaoLihong V Wang
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·H F Dvorak
Jul 15, 2006·Journal of Thrombosis and Haemostasis : JTH·S ZareiU M Vischer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.